Meniere Disease - Pipeline Review, H1 2018

Publisher Name :
Date: 27-Feb-2018
No. of pages: 44
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meniere Disease - Pipeline Review, H1 2018, provides an overview of the Meniere Disease (Ear Nose Throat Disorders) pipeline landscape.

Meniere disease is a disorder of the inner ear that causes spontaneous episodes of vertigo. Signs and symptoms of Meniere disease are hearing loss, tinnitus and feeling of fullness in the ear. Causes include allergies, viral infection, head trauma and migraines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Meniere Disease - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Meniere Disease (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Meniere Disease (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Meniere Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 2 respectively.

Meniere Disease (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note : Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Meniere Disease (Ear Nose Throat Disorders).

  • The pipeline guide reviews pipeline therapeutics for Meniere Disease (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Meniere Disease (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Meniere Disease (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Meniere Disease (Ear Nose Throat Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Meniere Disease (Ear Nose Throat Disorders).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Meniere Disease (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Meniere Disease - Pipeline Review, H1 2018

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Meniere Disease - Overview
Meniere Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Meniere Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Meniere Disease - Companies Involved in Therapeutics Development
Auris Medical Holding AG
Orbis Biosciences Inc
Otonomy Inc
Quark Pharmaceuticals Inc
Sound Pharmaceuticals Inc
Synphora AB
Meniere Disease - Drug Profiles
betahistine dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
betamethasone valerate ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexamethasone SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ebselen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QPHL-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Meniere Disease - Dormant Projects
Meniere Disease - Product Development Milestones
Featured News & Press Releases
Nov 08, 2017: Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX in Patients with Ménière's Disease
Oct 03, 2017: Sound Pharmaceuticals announces positive Phase 1b results and the start of a Phase 2b clinical trial in Menieres Disease
Aug 30, 2017: Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX in Patients with Menieres Disease
Jun 27, 2017: Sound Pharmaceuticals completes enrollment on Meniere Disease clinical trial
Jun 20, 2017: Otonomy to Host Key Opinion Leader Meeting for Investors on Meniere Disease
Mar 20, 2017: Sound Pharmaceuticals announces $1.6 Million Award from Cystic Fibrosis Foundation Therapeutics to prevent and treat the hearing loss and tinnitus associated with antibiotic use
Feb 03, 2017: Auris Medical Expands Clinical Development Pipeline with Intranasal Betahistine for the Treatment of Meniere Disease and Vestibular Vertigo
Jan 19, 2017: Otonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss
Aug 01, 2016: Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Meniere Disease Patients
Mar 23, 2016: Otonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in Ménière's Disease
Jan 26, 2016: Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss
Jan 05, 2016: FDA allows Sound Pharmaceuticals to begin Meniere Disease clinical trial
Nov 18, 2015: Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere Disease
Sep 24, 2015: Otonomy to Present Results for OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting
Sep 09, 2015: Otonomy Announces Successful End-of-Phase 2 Meeting With the FDA for OTO-104 in Meniere Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Meniere Disease, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Meniere Disease - Pipeline by Auris Medical Holding AG, H1 2018
Meniere Disease - Pipeline by Orbis Biosciences Inc, H1 2018
Meniere Disease - Pipeline by Otonomy Inc, H1 2018
Meniere Disease - Pipeline by Quark Pharmaceuticals Inc, H1 2018
Meniere Disease - Pipeline by Sound Pharmaceuticals Inc, H1 2018
Meniere Disease - Pipeline by Synphora AB, H1 2018
Meniere Disease - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Meniere Disease, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global ENT Disorder Treatment Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 122
    Report Overview: ENT is a medical abbreviation for ears, nose and throat. The Global ENT Disorder Treatment Market Size was estimated at USD 8522.90 million in 2022 and is projected to reach USD 10200.44 million by 2029, exhibiting a CAGR of 2.60% during the forecast period. This report provides a deep insight into the global ENT Disorder Treatment market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, co......
  • Global Tinnitus Drug Market Research Report 2023
    Published: 01-Dec-2023        Price: US 2900 Onwards        Pages: 89
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Tinnitus Drug market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Pfizer - Actavis - Teva - Mylan - Sun Pharmaceutical - Sandoz - Mallinckrodt - Taro Pharmaceutical Segment by Type - E......
  • Global Tinnitus Drug Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 02-May-2023        Price: US 3260 Onwards        Pages: 120
    Tinnitus is the hearing of sound when no external sound is present. While often described as a ringing, it may also sound like a clicking, hiss or roaring. The Tinnitus Drug market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Tinnitus Drug industry, and breaks down according to the type, application, and consumption area......
  • Global ENT Disorder Treatment Market Research Report 2023
    Published: 12-Apr-2023        Price: US 2900 Onwards        Pages: 86
    ENT is a medical abbreviation for ears, nose and throat. Highlights The global ENT Disorder Treatment market was valued at US$ 7306.4 million in 2022 and is anticipated to reach US$ 8522.9 million by 2029, witnessing a CAGR of 2.6% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes. Major factor contributing to growth of the global ENT disorder treatment market includes increasing pollution......
  • Global Tinnitus Drug Market Research Report 2023, Forecast to 2028
    Published: 10-Apr-2023        Price: US 2680 Onwards        Pages: 133
    There are presently no FDA-approved drugs specifically for tinnitus, and no medications that have been shown to reverse the neural hyperactivity at the root of tinnitus. Drugs cannot cure tinnitus, but they may provide relief from some severe tinnitus symptoms. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. ......
  • Global Tinnitus Drug Professional Survey Report 2023, Forecast to 2028
    Published: 10-Apr-2023        Price: US 3280 Onwards        Pages: 105
    There are presently no FDA-approved drugs specifically for tinnitus, and no medications that have been shown to reverse the neural hyperactivity at the root of tinnitus. Drugs cannot cure tinnitus, but they may provide relief from some severe tinnitus symptoms. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. ......
  • Global Tinnitus Drug Market Growth 2023-2029
    Published: 02-Feb-2023        Price: US 3660 Onwards        Pages: 92
    LPI (LP Information)' newest research report, the "Tinnitus Drug Industry Forecast" looks at past sales and reviews total world Tinnitus Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Tinnitus Drug sales for 2023 through 2029. With Tinnitus Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tinnitus Drug industry. This Insight Report provides a comprehensive ......
  • Tinnitus Drug Market, Global Outlook and Forecast 2023-2029
    Published: 31-Jan-2023        Price: US 3250 Onwards        Pages: 78
    This report aims to provide a comprehensive presentation of the global market for Tinnitus Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tinnitus Drug. This report contains market size and forecasts of Tinnitus Drug in global, including the following market information: Global Tinnitus Drug M......
  • Global Tinnitus Drug Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
    Published: 24-Jan-2023        Price: US 3480 Onwards        Pages: 90
    According to our (Global Info Research) latest study, the global Tinnitus Drug market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes. This report is a detailed and comprehensive analysis for global Tinnitus Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by regio......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs